Log in

NASDAQ:OPGN - OpGen Stock Price, Forecast & News

+0.07 (+4.29 %)
(As of 02/19/2020 08:39 AM ET)
Today's Range
Now: $1.70
50-Day Range
MA: $1.59
52-Week Range
Now: $1.70
Volume214,214 shs
Average Volume1.50 million shs
Market Capitalization$9.52 million
P/E RatioN/A
Dividend YieldN/A
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the United States and internationally. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Current SymbolNASDAQ:OPGN



Sales & Book Value

Annual Sales$2.95 million
Book Value$7.66 per share


Net Income$-13,370,000.00
Net Margins-397.44%


Market Cap$9.52 million
Next Earnings Date2/25/2020 (Estimated)
OptionableNot Optionable

Receive OPGN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPGN and its competitors with MarketBeat's FREE daily newsletter.

OpGen (NASDAQ:OPGN) Frequently Asked Questions

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

When did OpGen's stock split? How did OpGen's stock split work?

OpGen's stock reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of OpGen stock prior to the reverse split would have 4 shares after the split.

How were OpGen's earnings last quarter?

OpGen Inc (NASDAQ:OPGN) posted its quarterly earnings results on Wednesday, November, 6th. The medical research company reported ($3.34) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.60) by $0.74. The medical research company had revenue of $0.65 million for the quarter, compared to analysts' expectations of $0.90 million. OpGen had a negative return on equity of 662.90% and a negative net margin of 397.44%. View OpGen's Earnings History.

When is OpGen's next earnings date?

OpGen is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for OpGen.

What guidance has OpGen issued on next quarter's earnings?

OpGen issued an update on its FY 2019 After-Hours earnings guidance on Wednesday, February, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.5-3.5 million, compared to the consensus revenue estimate of $3.55 million.

What price target have analysts set for OPGN?

3 Wall Street analysts have issued 12 month price targets for OpGen's shares. Their forecasts range from $1.50 to $20.00. On average, they anticipate OpGen's share price to reach $7.93 in the next twelve months. This suggests a possible upside of 366.7% from the stock's current price. View Analyst Price Targets for OpGen.

What is the consensus analysts' recommendation for OpGen?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OpGen.

What are Wall Street analysts saying about OpGen stock?

Here are some recent quotes from research analysts about OpGen stock:
  • 1. According to Zacks Investment Research, "OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. " (2/5/2020)
  • 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $71M. This includes a discounted cash flow analysis based enterprise value of $72M for the QuickFISH and Acuitas products, with a 15% discount rate and 2% terminal growth rate, excluding $1M debt." (5/19/2019)

Has OpGen been receiving favorable news coverage?

News headlines about OPGN stock have trended very negative on Wednesday, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. OpGen earned a news impact score of -3.7 on InfoTrie's scale. They also gave media coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for OpGen.

Are investors shorting OpGen?

OpGen saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 80,900 shares, a drop of 61.7% from the January 15th total of 211,200 shares. Based on an average daily volume of 865,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.5% of the company's stock are sold short. View OpGen's Current Options Chain.

Who are some of OpGen's key competitors?

What other stocks do shareholders of OpGen own?

Who are OpGen's key executives?

OpGen's management team includes the folowing people:
  • Mr. Evan Jones, Chairman & CEO (Age 62)
  • Mr. Timothy C. Dec, CFO & Corp. Sec. (Age 60)
  • Mr. Vadim Sapiro, Chief Information Officer (Age 48)
  • Mr. Michael Farmer, VP of Marketing
  • Dr. G. Terrance Walker Ph.D., Sr. VP of R&D (Age 60)

When did OpGen IPO?

(OPGN) raised $17 million in an initial public offering (IPO) on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group acted as the underwriter for the IPO and National Securities was co-manager.

Who are OpGen's major shareholders?

OpGen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.22%), Virtu Financial LLC (0.96%) and Oxford Asset Management LLP (0.41%). View Institutional Ownership Trends for OpGen.

Which institutional investors are buying OpGen stock?

OPGN stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Renaissance Technologies LLC and Oxford Asset Management LLP. View Insider Buying and Selling for OpGen.

How do I buy shares of OpGen?

Shares of OPGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $1.70.

How big of a company is OpGen?

OpGen has a market capitalization of $9.52 million and generates $2.95 million in revenue each year. The medical research company earns $-13,370,000.00 in net income (profit) each year or ($44.40) on an earnings per share basis. OpGen employs 44 workers across the globe.View Additional Information About OpGen.

What is OpGen's official website?

The official website for OpGen is http://www.opgen.com/.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The medical research company can be reached via phone at 240-813-1260 or via email at [email protected]

MarketBeat Community Rating for OpGen (NASDAQ OPGN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  538
MarketBeat's community ratings are surveys of what our community members think about OpGen and other stocks. Vote "Outperform" if you believe OPGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel